Literature DB >> 19221959

Environmental triggers and susceptibility factors in idiopathic granulomatous diseases.

Paolo Spagnolo1, Luca Richeldi, Roland M du Bois.   

Abstract

Our understanding of the pathophysiology of granulomatous diseases has increased substantially during the past few years. However, despite many environmental agents (particularly of infectious origin) capable of inducing granulomatous inflammation, we do not know why only a small percentage of exposed individuals develop the disease, suggesting that a particular trigger results in overtly recognizable phenotypes only when the appropriate genetic trait also occurs. This review focuses on a research area that has been intensively investigated recently, and reports evidence for an individual predisposition to develop pulmonary granulomatous diseases of unknown origin, specifically sarcoidosis, Blau syndrome, and systemic vasculitides. Recent findings reinforce the hypothesis that transmissible agents, particularly mycobacteria, may be causative in some sarcoidosis cases, but the matter remains controversial due to the inability to consistently isolate microorganisms in pathological specimens. Whatever the etiology, future studies should focus on specific disease phenotypes to identify more homogeneous populations for analysis. This approach proved to be fruitful in both sarcoidosis and Wegener granulomatosis, suggesting that stratification of data by clinical phenotypes may discover genetic associations that analysis of disease susceptibility alone would fail to detect. Unraveling how genetic risk factors and environmental triggers interact to determine the disease is challenging but will inevitably have an impact on both diagnostic and therapeutic strategies in granulomatous lung diseases.

Entities:  

Mesh:

Year:  2009        PMID: 19221959     DOI: 10.1055/s-0028-1101271

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  9 in total

1.  ACE gene variants and sarcoidosis in a Finnish population.

Authors:  Elisa Lahtela; Annika Wennerström; Anne Pietinalho; Martin Petrek; Vitezslav Kolek; Marja-Liisa Lokki; Olof Selroos
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 2.  Sarcoidosis: a Critical Review of History and Milestones.

Authors:  Paolo Spagnolo
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

Review 3.  Immunogenetics of Disease-Causing Inflammation in Sarcoidosis.

Authors:  Johan Grunewald; Paolo Spagnolo; Jan Wahlström; Anders Eklund
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

4.  Hypersensitivity Pneumonitis With and Without Autoimmune Features: A Clinical Comparative Analysis.

Authors:  Saminder Singh Kalra; Johnny F Jaber; Bashar Alzghoul; Brandon Jansen; Ayoub Innabi; Amy B Tran; Katherine Fu; Raju Reddy; Diana C Gomez Manjarres; Divya Patel
Journal:  Lung       Date:  2022-10-18       Impact factor: 3.777

5.  Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement.

Authors:  K Zycinska; K A Wardyn; T M Zielonka; R Krupa; W Lukas
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

Review 6.  Hypersensitivity pneumonitis: a complex lung disease.

Authors:  Gian Galeazzo Riario Sforza; Androula Marinou
Journal:  Clin Mol Allergy       Date:  2017-03-07

7.  SNP Variants in Major Histocompatibility Complex Are Associated with Sarcoidosis Susceptibility-A Joint Analysis in Four European Populations.

Authors:  Annika Wolin; Elisa Laura Lahtela; Verneri Anttila; Martin Petrek; Johan Grunewald; Coline H M van Moorsel; Anders Eklund; Jan C Grutters; Vitezslav Kolek; Frantisek Mrazek; Amit Kishore; Leonid Padyukov; Anne Pietinalho; Marcus Ronninger; Mikko Seppänen; Olof Selroos; Marja-Liisa Lokki
Journal:  Front Immunol       Date:  2017-04-19       Impact factor: 7.561

8.  Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: a national population-based study.

Authors:  Anne Hald Rittig; Ole Hilberg; Rikke Ibsen; Anders Løkke
Journal:  ERJ Open Res       Date:  2019-10-21

Review 9.  Genetic testing in diffuse parenchymal lung disease.

Authors:  Paolo Spagnolo; Fabrizio Luppi; Stefania Cerri; Luca Richeldi
Journal:  Orphanet J Rare Dis       Date:  2012-10-17       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.